vs

Side-by-side financial comparison of BayCom Corp (BCML) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). BayCom Corp runs the higher net margin — 26.5% vs -177.4%, a 203.9% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs -11.5%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-23.1M). Over the past eight quarters, BayCom Corp's revenue compounded faster (2.9% CAGR vs -12.2%).

BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BCML vs LAB — Head-to-Head

Bigger by revenue
BCML
BCML
1.3× larger
BCML
$25.9M
$19.6M
LAB
Growing faster (revenue YoY)
BCML
BCML
+20.9% gap
BCML
9.4%
-11.5%
LAB
Higher net margin
BCML
BCML
203.9% more per $
BCML
26.5%
-177.4%
LAB
More free cash flow
BCML
BCML
$53.2M more FCF
BCML
$30.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
BCML
BCML
Annualised
BCML
2.9%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BCML
BCML
LAB
LAB
Revenue
$25.9M
$19.6M
Net Profit
$6.9M
$-34.7M
Gross Margin
48.5%
Operating Margin
36.6%
-168.5%
Net Margin
26.5%
-177.4%
Revenue YoY
9.4%
-11.5%
Net Profit YoY
12.1%
-28.8%
EPS (diluted)
$0.63
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCML
BCML
LAB
LAB
Q4 25
$25.9M
Q3 25
$25.7M
$19.6M
Q2 25
$24.7M
$21.8M
Q1 25
$24.3M
$40.8M
Q4 24
$23.7M
Q3 24
$25.6M
$22.1M
Q2 24
$23.8M
$22.5M
Q1 24
$24.5M
$45.5M
Net Profit
BCML
BCML
LAB
LAB
Q4 25
$6.9M
Q3 25
$5.0M
$-34.7M
Q2 25
$6.4M
$-33.5M
Q1 25
$5.7M
$-26.0M
Q4 24
$6.1M
Q3 24
$6.0M
$-26.9M
Q2 24
$5.6M
$-45.7M
Q1 24
$5.9M
$-32.2M
Gross Margin
BCML
BCML
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
BCML
BCML
LAB
LAB
Q4 25
36.6%
Q3 25
26.3%
-168.5%
Q2 25
35.3%
-118.1%
Q1 25
31.6%
-80.8%
Q4 24
34.2%
Q3 24
32.4%
-120.9%
Q2 24
31.9%
-134.5%
Q1 24
33.3%
-132.2%
Net Margin
BCML
BCML
LAB
LAB
Q4 25
26.5%
Q3 25
19.5%
-177.4%
Q2 25
25.8%
-153.7%
Q1 25
23.4%
-63.8%
Q4 24
25.9%
Q3 24
23.5%
-122.0%
Q2 24
23.6%
-203.3%
Q1 24
24.0%
-70.6%
EPS (diluted)
BCML
BCML
LAB
LAB
Q4 25
$0.63
Q3 25
$0.46
$-0.09
Q2 25
$0.58
$-0.09
Q1 25
$0.51
$-0.07
Q4 24
$0.55
Q3 24
$0.54
$-0.07
Q2 24
$0.50
$-0.12
Q1 24
$0.51
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCML
BCML
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.6M
$399.7M
Total Assets
$2.6B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCML
BCML
LAB
LAB
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
BCML
BCML
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
BCML
BCML
LAB
LAB
Q4 25
$338.6M
Q3 25
$334.3M
$399.7M
Q2 25
$330.6M
$424.5M
Q1 25
$329.3M
$454.6M
Q4 24
$324.4M
Q3 24
$321.7M
$489.3M
Q2 24
$315.3M
$510.3M
Q1 24
$314.2M
$577.3M
Total Assets
BCML
BCML
LAB
LAB
Q4 25
$2.6B
Q3 25
$2.6B
$539.6M
Q2 25
$2.6B
$557.0M
Q1 25
$2.6B
$579.6M
Q4 24
$2.7B
Q3 24
$2.6B
$681.5M
Q2 24
$2.6B
$708.7M
Q1 24
$2.6B
$777.7M
Debt / Equity
BCML
BCML
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCML
BCML
LAB
LAB
Operating Cash FlowLast quarter
$31.8M
$-22.2M
Free Cash FlowOCF − Capex
$30.1M
$-23.1M
FCF MarginFCF / Revenue
116.2%
-118.1%
Capex IntensityCapex / Revenue
6.7%
4.5%
Cash ConversionOCF / Net Profit
4.64×
TTM Free Cash FlowTrailing 4 quarters
$51.1M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCML
BCML
LAB
LAB
Q4 25
$31.8M
Q3 25
$7.3M
$-22.2M
Q2 25
$6.4M
$-20.7M
Q1 25
$9.3M
$-30.3M
Q4 24
$30.4M
Q3 24
$9.6M
$-27.9M
Q2 24
$7.7M
$-39.0M
Q1 24
$5.1M
$-62.5M
Free Cash Flow
BCML
BCML
LAB
LAB
Q4 25
$30.1M
Q3 25
$6.2M
$-23.1M
Q2 25
$5.6M
$-22.6M
Q1 25
$9.1M
$-35.3M
Q4 24
$28.7M
Q3 24
$9.4M
$-30.1M
Q2 24
$7.4M
$-41.0M
Q1 24
$3.9M
$-63.3M
FCF Margin
BCML
BCML
LAB
LAB
Q4 25
116.2%
Q3 25
24.3%
-118.1%
Q2 25
22.8%
-103.6%
Q1 25
37.6%
-86.6%
Q4 24
121.1%
Q3 24
36.6%
-136.4%
Q2 24
31.2%
-182.2%
Q1 24
16.1%
-138.9%
Capex Intensity
BCML
BCML
LAB
LAB
Q4 25
6.7%
Q3 25
4.3%
4.5%
Q2 25
3.0%
8.7%
Q1 25
0.6%
12.4%
Q4 24
7.2%
Q3 24
1.0%
10.2%
Q2 24
1.0%
8.6%
Q1 24
4.7%
1.7%
Cash Conversion
BCML
BCML
LAB
LAB
Q4 25
4.64×
Q3 25
1.47×
Q2 25
1.00×
Q1 25
1.63×
Q4 24
4.96×
Q3 24
1.60×
Q2 24
1.37×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCML
BCML

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons